Overall survival (OS) in patients with EGFR-mutated new diagnosed stage IIIB/IV NSCLC in addiction of exon 19, 18/20 and 21 mutation and in addiction of treatment with tyrosine kinase inhibitor (TKI) or chemotherapy: A subgroup analysis of the REASON trial.-Reference-Cited by-同舟云学术

Overall survival (OS) in patients with EGFR-mutated new diagnosed stage IIIB/IV NSCLC in addiction of exon 19, 18/20 and 21 mutation and in addiction of treatment with tyrosine kinase inhibitor (TKI) or chemotherapy: A subgroup analysis of the REASON trial.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:e19001-e19001
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Schuette Wolfgang¹,Behlendorf Timo²,Schirmacher Peter³,Eberhardt Wilfried⁴,Dietel Manfred⁵,Zirrgiebel Ute⁶,Muehlenhoff Lars⁷,Thomas Michael⁸

Affiliation:

1. Hospital Martha-Maria Halle-Doelau, Halle, Germany

2. Hospital Martha-Maria Halle-Dölau, Halle, Germany

3. Pathologisches Institut Universität Heidelberg, Heidelberg, Germany

4. Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany

5. Institute of Pathology, Charité Universitätsmedizin, Berlin, Germany

6. iOMEDICO AG, Freiburg, Germany

7. AstraZeneca GmbH, Wedel, Germany

8. Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2015.33.15_suppl.e19001

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC;Future Oncology;2021-02